Main Menu

The described technology pertains to the development of bispecific antibodies targeting the Ebola virus glycoprotein. These antibodies, mAb114 and either S1-4-A09 or its engineered variant S1-4-A09 A80P, demonstrate specificity towards the Ebola virus (EBOV) glycoproteins from different strains, including Kikwit and Bundibugyo. The variant S1-4-A09 A80P retains binding specificity and activity but lacks a glycosylation motif, enhancing manufacturability without compromising function.

Novel CD8+ T cell receptors (TCRs) isolated from elite HIV controllers show unprecedented affinity for conserved HIV epitopes, offering new avenues for direct immunotherapies and T cell engineering. These TCRs exhibit potential for cytotoxicity mediation against HIV-infected cells, with prospects for use in toxin-coupled treatments or as part of engineered T cell therapies. Collaborations, such as with Altor Biosciences, are enhancing these TCRs with proprietary molecules like IL-15, to bolster therapeutic efficacy.

The technology described pertains to the development of bispecific antibodies with enhanced ability to neutralize HIV-1. By structurally designing single chain fragment variable antibodies that join variable regions of multiple broadly neutralizing antibodies (bNAbs) with flexible linkers, the research has yielded a bispecific antibody that targets different epitopes on the HIV-1 envelope. The combination of VRC01—targeting the CD4 binding site—and PGT121—targeting the V3 glycan—has shown promising results.

The technology revolves around an innovative monoclonal antibody-based conditioning regimen for enhancing the engraftment of hematopoietic stem cells during bone marrow transplants. It features a novel antibody-drug conjugate that targets CD117, a marker on stem cells, to enable effective transplantation without the harmful side effects of traditional conditioning methods.

The technology in focus encompasses a novel suite of synthetic peptide immunogens, collaboratively developed by leading institutions, aimed at evoking a robust immune response against HIV-1. This breakthrough harnesses the latest advancements in immunology to craft immunogens that elicit broadly neutralizing antibodies in humans, a significant stride in HIV-1 therapeutic and preventive strategies.

The technology pertains to a novel polymer nanoparticle platform designed for the creation of individualized cancer vaccines. It utilizes a two-component system that combines patient-specific peptide neoantigens with immunostimulants within self-assembling nanoparticles. This approach ensures the targeted delivery of neoantigens to the immune system, enhancing the immune response against cancer cells while avoiding the systemic activation often seen with conventional adjuvants.

The technology outlined in the document is focused on the discovery of novel biomarkers for Onchocerciasis, a parasitic disease also known as river blindness, which is transmitted by blackfly vectors. The document describes the identification of the first Onchocerca volvulus-encoded molecules that are adult-specific and can be used as markers for macrofilaricidal activity, which is the ability to kill adult worms.

The technology is centered around the Real Time Quaking Induced Conversion (RT-QuIC) assay, which aims to enhance the detection and discrimination of prion diseases in humans and animals. This assay utilizes recombinant prion protein (rPrPSen) to detect prion-seeded fibrillization, offering a highly specific and ultra-sensitive method for detecting multiple prion diseases across various species. A key innovation of the technology is the use of recombinant bank vole prion protein as a broadly reactive substrate. This substrate, when expressed in E.

The technology encompasses a novel set of fully human monoclonal antibodies targeting the spike (S) protein of coronaviruses, notably the SARS-CoV-2 virus responsible for COVID-19. These antibodies, derived from convalescent patients, offer potential for use in the diagnosis, monitoring, and treatment of coronavirus infections. This discovery includes a comprehensive library of antibody or antibody fragment candidates with high specificity for the coronavirus spike protein.

This technology presents a novel strain of transgenic mice where the proto-oncogene c-Cbl (Casitas B-lineage lymphoma) has been engineered with loxP (locus of X-over P1) sites, commonly referred to as "floxed." This design enables the conditional knockout of the c-Cbl gene when the mice are crossed with strains that express the Cre recombinase enzyme. Cre recombinase is an enzyme that can specifically target loxP sites, excising the floxed gene only in the presence of Cre, thus allowing tissue-specific or temporal deletion of the target gene.